Respiratory Pathogen Panel TEM-PCR™
This assay detects respiratory Coronaviruses only. This assay does NOT detect if the patient is positive for the novel 2019 Coronavirus out of China.
Please see Coronavirus (COVID-19) SARS-CoV-2 Test
The Respiratory Pathogen Panel detects 26 pathogens (viral and bacterial) using TEM-PCRTM (Target Enriched Multiplex Polymerase Chain Reaction) technology - a multiplex PCR amplification technology to detect multiple targets simultaneously. Multiple target panel testing helps identify co-infections, provides physicians with valuable diagnostic insight into unknown causes of infection, reduces unnecessary antibiotic administration and hospital acquired infections, allows for molecular testing in patients with concurrent antibiotic use, and more targeted therapy for better patient management and overall reduced hospital costs.
About Respiratory Pathogen Panel
This assay detects the majority of respiratory disease-causing viral and bacterial pathogens of critical importance to patients, including children, elderly, and the immunocompromised. An etiologic diagnosis of respiratory disease will lead to more effective and efficient management of patients, and play a key role in supporting Healthcare Reform and Antimicrobial Stewardship — helping to facilitate the CDC’s efforts to cross-communicate antibiotic-resistant bacteria data across the U.S. — to ultimately decrease the spread of infections and combat the increasingly devastating effects of “superbugs.”
ProcedureTarget Enriched Multiplex PCRTM diagnostic panel testing consists of three major steps: extraction, amplification and detection. The key to making TEM-PCRTM occur successfully lies in these primer mixes and how they allow the enrichment of multiple targets. The use of target-specific nested primers at low concentrations at the initial enrichment step allows high specificity of multiplexing amplification. After initial target enrichment is complete, Super Primers within the reaction carry out the exponential amplification and produce tagged PCR products for subsequent detection. The detection phase of the process is accomplished by measuring the fluorescence of special tags that are bound to the target sequences, which have been attached during amplification. This test has not been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.
SpecificityThe Adenovirus assay detects Serotypes B and E. Detection of Serotype C may be limited. If Adenovirus infection is suspected and a Not Detected result is returned, the sample should be re-tested for Adenovirus using an independent method (e.g. Viracor Eurofins Adenovirus Quantitative Real-time PCR test).
Within 24 hours from receipt of specimen, Monday through Saturday.
| Specimen Type | Test Code | CPT Code | NY Approved | Volume | Assay Range | Special Instructions |
|---|---|---|---|---|---|---|
| BAL | 220098 | 87798 (x9), 87541 (x1), 87486 (x1), 87581 (x1), 87632 (x1), 87641 (x1), 87651 (x1) | No | 2 mL (min. 0.5 mL) |
Positive/Not Detected |
|
| bronch wash | 220098 | 87798 (x9), 87541 (x1), 87486 (x1), 87581 (x1), 87632 (x1), 87641 (x1), 87651 (x1) | No | 2 mL (min. 0.5 mL) |
Positive/Not Detected |
|
| nasal asp | 220098 | 87798 (x9), 87541 (x1), 87486 (x1), 87581 (x1), 87632 (x1), 87641 (x1), 87651 (x1) | No | 2 mL (min. 0.5 mL) |
Positive/Not Detected |
|
| nasal swab | 220098 | 87798 (x9), 87541 (x1), 87486 (x1), 87581 (x1), 87632 (x1), 87641 (x1), 87651 (x1) | No | 2 mL |
Positive/Not Detected |
|
| nasal wash | 220098 | 87798 (x9), 87541 (x1), 87486 (x1), 87581 (x1), 87632 (x1), 87641 (x1), 87651 (x1) | No | 2 mL (min. 0.5 mL) |
Positive/Not Detected |
|
| NP aspirate | 220098 | 87798 (x9), 87541 (x1), 87486 (x1), 87581 (x1), 87632 (x1), 87641 (x1), 87651 (x1) | No | 2 mL (min. 0.5 mL) |
Positive/Not Detected |
|
| NP swab | 220098 | 87798 (x9), 87541 (x1), 87486 (x1), 87581 (x1), 87632 (x1), 87641 (x1), 87651 (x1) | No | 2 mL |
Positive/Not Detected |
|
| NP Wash (1) | 220098 | 87798 (x9), 87541 (x1), 87486 (x1), 87581 (x1), 87632 (x1), 87641 (x1), 87651 (x1) | No | 2 mL (min. 0.5 mL) |
Positive/Not Detected |
|
| sputum | 220098 | 87798 (x9), 87541 (x1), 87486 (x1), 87581 (x1), 87632 (x1), 87641 (x1), 87651 (x1) | No | 2 mL (min. 0.5 mL) |
Positive/Not Detected |
|
| throat gargle | 220098 | 87798 (x9), 87541 (x1), 87486 (x1), 87581 (x1), 87632 (x1), 87641 (x1), 87651 (x1) | No | 2 mL (min. 0.5 mL) |
Positive/Not Detected |
|
| trach asp | 220098 | 87798 (x9), 87541 (x1), 87486 (x1), 87581 (x1), 87632 (x1), 87641 (x1), 87651 (x1) | No | 2 mL (min. 0.5 mL) |
Positive/Not Detected |
|
| trach wash | 220098 | 87798 (x9), 87541 (x1), 87486 (x1), 87581 (x1), 87632 (x1), 87641 (x1), 87651 (x1) | No | 2 mL (min. 0.5 mL) |
Positive/Not Detected |
|
Ship Monday through Friday. Friday shipments must be labeled for Saturday delivery. All specimens must be labeled with patient's name and collection date. A Viracor Eurofins test requisition form must accompany each specimen. Multiple tests can be run on one specimen. Ship specimens FedEx Priority Overnight® to: Viracor Eurofins, 18000 W 99th St. Ste, #10, Lenexa, KS 66219.
Causes for RejectionWood shafted swab, calcium alginate swab, specimens received in trap containers, specimens beyond their acceptable length of time from collection as listed in the specimen handling, or specimen types other than those listed.
Specimens are approved for testing in New York only when indicated in the Specimen Information field above. The CPT codes provided are based on Viracor Eurofins' interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Viracor Eurofins assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.